Check Out The Dean’s VRAL Dream Team
June 26th, 2009 at 2:53 am Posted by The Dean
One of the most important lessons I teach is that the ‘smart money’ will invest in people. It’s the #1 reason why Viral Genetics (VRAL) is at the very top of The Dean’s List. VRAL has attracted some of the most influential leaders in the medical community including:
- A Nobel Prize Winner;
- A Former U.S. Surgeon General;
- Specialists at Harvard Medical School; and
- Microsoft’s lead patent attorney.
Dr. Montagnier is best known for his 1983 discovery of the human immunodeficiency virus (HIV), which has been identified as the cause of AIDS. He has received more than 20 major awards including the 2008 Nobel Prize in Medicine for the discovery of HIV.
Dr. Charles Koop was the U.S. Surgeon General under the Reagan administration when AIDS was a deadly enigma. In 1988, Dr. Koop wrote “Understanding AIDS,” a Public Heath Service brochure based on CDC guidelines, which was sent to all 107 million households in the U.S. It was the largest mailing ever by the federal government.
Dr. Eric S. Rosenberg has an extensive background studying HIV. He is best known for his research on early HIV infection as an Assistant Professor of Harvard Medical School.
Marshall Phelps, Jr. is currently Corporate Vice President for IP Policy and Strategy for Microsoft. Mr. Phelps is responsible for establishing global policy and strategy for Microsoft’s intellectual property, and interfacing with governments and technology companies about intellectual property issues.
Can you imagine what VRAL will trade for once biotech investors learn about these influential names??? And to think that the Wide World of Stocks will feature VRAL so soon!
I could be wrong, but I think the original discoverer of HIV would be very knowledgeable about a potential HIV cure and wouldn’t be an advisor to VRAL if he didn’t believe in the science.
Hey VRAL has potential in the future, with its patents sold to such other large pharma companies, but not now. I’ve had this stock for about a year, bought it at $ .008 40000 shares. With Obama and new healthcare system VRAL will make money.
You should look at FEEC. Its going to go balastic in 2011. but at todays price its a major steal.